
Stanford Health Care’s Janjri Desai, Pharm.D., says pharmacists improve outcomes but often can’t bill for it, making billing parity key to growing services.
One driver involved in managing injectables is the product selection process. Historically, injectable products were introduced into the market as new innovations for previously untreated or undertreated diseases. While manufacturers continue to introduce products that are therapy class innovations, there has been a recent trend to release injectable products that serve as secondary or tertiary biotech additions to a particular therapy class.